Bridger Management LLC purchased a new stake in Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 905,998 shares of the biopharmaceutical company’s stock, valued at approximately $8,181,000. Bridger Management LLC owned 1.75% of Dicerna Pharmaceuticals at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of DRNA. Northern Trust Corp boosted its holdings in Dicerna Pharmaceuticals by 6.1% in the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 2,094 shares during the period. Vanguard Group Inc. boosted its holdings in Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after purchasing an additional 14,517 shares during the period. First Manhattan Co. bought a new stake in Dicerna Pharmaceuticals in the 4th quarter valued at $3,865,000. Emerald Advisers Inc. PA bought a new stake in Dicerna Pharmaceuticals in the 4th quarter valued at $266,000. Finally, Monashee Investment Management LLC bought a new stake in Dicerna Pharmaceuticals in the 4th quarter valued at $1,878,000. 75.49% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have weighed in on the stock. Stifel Nicolaus increased their price target on shares of Dicerna Pharmaceuticals from $10.00 to $17.00 and gave the company a “buy” rating in a report on Friday. Chardan Capital assumed coverage on shares of Dicerna Pharmaceuticals in a report on Friday. They issued a “neutral” rating for the company. BidaskClub raised shares of Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, February 28th. ValuEngine raised shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, February 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Dicerna Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $11.21.
Dicerna Pharmaceuticals Inc (NASDAQ DRNA) opened at $14.12 on Monday. Dicerna Pharmaceuticals Inc has a one year low of $2.52 and a one year high of $15.00.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.25). Dicerna Pharmaceuticals had a negative net margin of 2,637.15% and a negative return on equity of 171.81%. The business had revenue of $1.40 million during the quarter, compared to analyst estimates of $1.45 million. The business’s revenue for the quarter was up 976.9% on a year-over-year basis. sell-side analysts forecast that Dicerna Pharmaceuticals Inc will post -2.86 earnings per share for the current fiscal year.
In other Dicerna Pharmaceuticals news, Director Bain Capital Life Sciences Inv acquired 285,000 shares of the company’s stock in a transaction dated Monday, December 18th. The stock was bought at an average price of $7.00 per share, for a total transaction of $1,995,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 29.41% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/03/12/905998-shares-in-dicerna-pharmaceuticals-inc-drna-purchased-by-bridger-management-llc.html.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.